NEW YORK – Eagle Genomics said Wednesday that it has formed a partnership with the Earlham Institute to develop technology and datasets to further the analysis of microbiome data.
The partnership will include collaborative research and development, consulting services, and technology licensing, centered around Eagle Genomics' e[datascientist] software platform. That product uses artificial intelligence to analyze genomic and microbiome data at scale for assessing the viability, efficacy, and safety of products.
Eagle and the Earlham institute said that their partnership could include support for research into classification and genome reconstruction, biomarker identification, global patterns of antimicrobial resistance, and the persistence and evolution of microbes associated with humans.
"Our new partnership with the Earlham Institute will help support the global microbiome R&D community while shaping the future of metagenomics, linking world-leading bioinformatics pipelines, tools, and datasets," Andrew Tingey, senior director for global licensing and intellectual property strategy at Cambridge, UK-based Eagle, said in a statement.
"This partnership is part of a big-data revolution in terms of how multiomics data will be accessed and analyzed, combining open science and commercial R&D to benefit each partner and society," added Liliya Serazetdinova, head of business development at the Norwich, UK-based Earlham Institute. "Eagle Genomics' e[datascientist] platform gives our scientists the opportunity to share their work more widely, establish new connections, and use it as a testing ground, interrogating and integrating new datasets, as well as developing new tools and pipelines, to further advance our research and apply [it] to the biotech industry."
Eagle raised a $9 million funding round in October 2020.